Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001104659-12-012152)

Filing Details

Accession Number:: 0001104659-12-012152
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2012-02-23 16:18:14
Reporting Period:: 2012-02-23

Filing Date:: 2012-02-23
Accepted Time:: 2012-02-23 16:18:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1093649	Idenix Pharmaceuticals Inc	IDIX	Pharmaceutical Preparations (2834)	450478605

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1030617	Ag Pharma Novartis	Lichstrasse 35 Basel V8 CH4002		No	No	Yes	No
1114448	Ag Novartis	Lichstrasse 35 Basel V8 CH4002		No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-02-23	35,735	$2.41	33,271,516	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	366	$2.47	33,271,882	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	2,493	$2.56	33,274,375	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	997	$2.69	33,275,372	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	997	$2.78	33,276,369	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	1,321	$2.85	33,277,690	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	3,117	$2.90	33,280,807	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	8,960	$2.96	33,289,767	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	427	$2.97	33,290,194	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	232	$3.04	33,290,426	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	4,336	$3.17	33,294,762	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	3,093	$3.79	33,297,855	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	39	$5.10	33,297,894	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	11,433	$5.11	33,309,327	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	7,402	$5.46	33,316,729	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	883	$5.79	33,317,612	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	436	$5.80	33,318,048	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	493	$6.52	33,318,541	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2012-02-23	2,133	$7.39	33,320,674	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

These securities are owned directly by Novartis Pharma AG, a direct, wholly-owned subsidiary of Novartis AG. Novartis AG is indirect beneficial owner of these securities. See attachment.